Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature

Thielen, A.-M.; Kuenzli, Stéphane; Saurat, J.‐H.

doi:10.1159/000087013

Cited by 55 publications

(52 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the concept of ‘granulomatous dermatitis with enlarged histiocytes’ seems an illustrative term to define this characteristic eruption. A similar clinicopathological feature has recently been described in a patient receiving TNF-α monoclonal antibody therapy [34]. …”

Section: Commentsupporting

confidence: 66%

Granulomatous Dermatitis with Enlarged Histiocytes: A Characteristic Pattern of Granulocyte Colony-Stimulating Factor

et al. 2006

View full text Add to dashboard Cite

Two patients developed a pruritic maculopapular rash following treatment with granulocyte colony-stimulating factor (G-CSF). Histopathological examination disclosed a superficial dermal inflammatory infiltrate composed of interstitially arranged large histiocytic CD68+ cells and perivascularly disposed lymphocytes. Large histiocytes were interspersed among the collagen bundles with associated slight deposits of mucin. Elastophagocytosis was occasionally observed, and a slight reduction of dermal elastic fibers was also noted. There was no evidence of frank granuloma formation, fibrosis or significant changes of collagen bundles. This histopathological variant of granulomatous dermatitis with ‘enlarged histiocytes’ seems to be characteristic of an unusual cutaneous reaction secondary to CSF treatment.

show abstract

Section: Commentsupporting

confidence: 66%

Granulomatous Dermatitis with Enlarged Histiocytes: A Characteristic Pattern of Granulocyte Colony-Stimulating Factor

et al. 2006

View full text Add to dashboard Cite

show abstract

“…A review of the skin adverse effects describing the different biological therapies has been published [15]. The administration of infliximab could provoke acute reactions to the infusion, estimated to happen in 5%, or retarded cutaneous eruptions.…”

Section: Discussionmentioning

confidence: 99%

Infliximab for the Treatment of Hidradenitis Suppurativa

Fernández–Vozmediano

Armario-Hita²

2007

Dermatology

View full text Add to dashboard Cite

Introduction: Hidradenitis suppurativa is a chronic inflammatory disease characterized by significant morbidity. Current medical therapies are usually only minimally effective. Objective: To assess the efficacy and safety of infliximab monotherapy for the treatment of severe extensive refractory forms of hidradenitis suppurativa. Design: A retrospective study in a group of 6 patients who received treatment with infliximab for hidradenitis suppurativa, in the Dermatology Department of the University Hospital of Puerto Real in the last year. The dose was 5–10 mg/kg at weeks 0, 2 and 6, followed by a maintenance dose every 4 weeks. Subjective and objective efficacy was assessed before and after each treatment session. Results: All patients experienced improvement in subjective symptoms after the initial dose. A decrease in exudation, the size and number of lesions and less development of fistulous tracts were observed. The patients were followed up during 6 months. Treatment was generally well tolerated and there was only one mild reaction to the infusion in the form of headache. No patient required treatment discontinuation due to adverse effects. Conclusions: Infliximab was shown to be an effective therapeutic alternative for severe extensive forms of hidradenitis suppurativa when it is used as monotherapy.

show abstract

“…Drug induced skin lesions represent the most frequent side effect of anti-TNFα agents, presumably in susceptible individuals [3][4][5][6][7][8][9][10]. They include infusion/ injection site reactions, psoriasis and psoriasis-like lesions, lupus-like syndromes, vasculitis, cutaneous infections, eczematous reactions, lichenoid reactions, cutaneous lymphomas, skin cancers and granulomatous diseases [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…They include infusion/ injection site reactions, psoriasis and psoriasis-like lesions, lupus-like syndromes, vasculitis, cutaneous infections, eczematous reactions, lichenoid reactions, cutaneous lymphomas, skin cancers and granulomatous diseases [5][6][7][8][9][10]. Many noninfectious cutaneous granulomatous reactions have been described in literature, such as granuloma annulare, cutaneous sarcoidosis and sarcoid-like granulomatosis [11,12].…”

Section: Introductionmentioning

confidence: 99%

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Cassone¹

2017

Clin Med Rev Case Rep

View full text Add to dashboard Cite

Tumor Necrosis Factor (TNF)-α blockers have been shown to be highly effective in the treatment of arthritis not responsive to traditional therapy. In parallel, there are an increasing number of reports about the development of cutaneous side effects after the administration of anti-TNF-α agents. Noninfectious cutaneous granulomatous reactions include granuloma annulare, non-caseating granuloma, sarcoid-like granulomatosis and also a wide spectrum of conditions recently unified under the term of reactive granulomatous dermatitis.The majority of the above reported granulomatous dermatitis is associated with an underlying inflammatory disorder, and almost all may be drug-induced. Moreover, a substantial overlap, both in clinical and histologic features, is present between these conditions. We describe a reactive granulomatous dermatitis in a patient with psoriatic arthritis treated with adalimumab, resolved after the TNF-α inhibitor discontinuation, and we summarize the recent case-reports in which reactive granulomatous dermatitis were observed in patients with arthritis receiving various TNF-α inhibitors. Reactive granulomatous dermatitis may be a possible long-term side effect of this class of drugs. Although TNF-α blockers are usually used in the treatment of granulomatous disorders, patients treated with these kinds of drugs should be carefully monitored as, in rare cases, TNF-α inhibitors may induce sufficient cytokine activation to support granuloma formation.

show abstract

Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature

Cited by 55 publications

References 67 publications

Granulomatous Dermatitis with Enlarged Histiocytes: A Characteristic Pattern of Granulocyte Colony-Stimulating Factor

Granulomatous Dermatitis with Enlarged Histiocytes: A Characteristic Pattern of Granulocyte Colony-Stimulating Factor

Infliximab for the Treatment of Hidradenitis Suppurativa

Reactive Granulomatous Dermatitis during Anti-TNF Therapy: A Case Report and Review of the Literature

Contact Info

Product

Resources

About